CN111093772B - 偏头痛的治疗 - Google Patents

偏头痛的治疗 Download PDF

Info

Publication number
CN111093772B
CN111093772B CN201880039532.2A CN201880039532A CN111093772B CN 111093772 B CN111093772 B CN 111093772B CN 201880039532 A CN201880039532 A CN 201880039532A CN 111093772 B CN111093772 B CN 111093772B
Authority
CN
China
Prior art keywords
migraine
acetylleucine
application
pharmaceutically acceptable
leucine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880039532.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN111093772A (zh
Inventor
M·施特鲁普
M·法克拓尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intrabio Ltd
Original Assignee
Intrabio Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59358204&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN111093772(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Intrabio Ltd filed Critical Intrabio Ltd
Publication of CN111093772A publication Critical patent/CN111093772A/zh
Application granted granted Critical
Publication of CN111093772B publication Critical patent/CN111093772B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201880039532.2A 2017-06-14 2018-06-25 偏头痛的治疗 Active CN111093772B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1709459.0A GB201709459D0 (en) 2017-06-14 2017-06-14 Treatment for migraine
PCT/IB2018/054676 WO2018229738A1 (en) 2017-06-14 2018-06-25 Treatment for migraine

Publications (2)

Publication Number Publication Date
CN111093772A CN111093772A (zh) 2020-05-01
CN111093772B true CN111093772B (zh) 2023-11-03

Family

ID=59358204

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880039532.2A Active CN111093772B (zh) 2017-06-14 2018-06-25 偏头痛的治疗

Country Status (25)

Country Link
US (1) US11471434B2 (https=)
EP (1) EP3638370B1 (https=)
JP (1) JP7130739B2 (https=)
KR (1) KR102594130B1 (https=)
CN (1) CN111093772B (https=)
AU (1) AU2018284330B2 (https=)
CY (1) CY1123860T1 (https=)
DK (1) DK3638370T3 (https=)
ES (1) ES2847169T3 (https=)
GB (1) GB201709459D0 (https=)
HR (1) HRP20210108T1 (https=)
HU (1) HUE053089T2 (https=)
IL (1) IL271211B2 (https=)
LT (1) LT3638370T (https=)
MA (1) MA49396B1 (https=)
MD (1) MD3638370T2 (https=)
MX (1) MX387909B (https=)
PL (1) PL3638370T3 (https=)
PT (1) PT3638370T (https=)
RS (1) RS61481B1 (https=)
SG (1) SG11201912146RA (https=)
SI (1) SI3638370T1 (https=)
SM (1) SMT202100037T1 (https=)
WO (1) WO2018229738A1 (https=)
ZA (1) ZA201908087B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA51836B1 (fr) * 2018-02-15 2025-01-31 Intrabio Ltd Agents thérapeutiques permettant de traiter le syndrome des jambes sans repos
EP3886986A1 (en) 2018-12-06 2021-10-06 IntraBio Ltd Deuterated analogs of acetyl-leucine

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4962121A (en) * 1987-04-22 1990-10-09 Anders Hamberger Method and composition for treating neurological diseases such as migraine
WO2008032222A2 (en) * 2006-09-13 2008-03-20 Pierre Fabre Medicament Treatment of vertigo with acetyl-l-leucine
CN103200940A (zh) * 2010-11-09 2013-07-10 曼金德公司 用于治疗偏头痛的包含血清素受体激动剂和二酮哌嗪的组合物

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040127501A1 (en) * 2002-09-24 2004-07-01 Zhengming Chen Therapeutic agents useful for treating pain
US20060063827A1 (en) 2004-09-23 2006-03-23 Yu Ruey J Systemic administration of therapeutic amino acids and N-acetylamino acids
TWI287010B (en) * 2003-06-12 2007-09-21 Euro Celtique Sa Therapeutic agents useful for treating pain
SI1641775T1 (sl) * 2003-07-03 2009-08-31 Euro Celtique Sa 2-piridin alkinski derivati, uporabni za zdravljenje bolečine
DE602004017316D1 (de) * 2003-07-24 2008-12-04 Euro Celtique Sa Heteroaryl-tetrahydropyridylverbindungen, die sich für die behandlung bzw. die prävention von schmerzen eignen
SI1664016T1 (sl) * 2003-09-22 2009-04-30 Euro Celtique Sa Terapevtska sredstva, uporabna za zdravljenje bolečine
PL1664041T3 (pl) * 2003-09-22 2008-12-31 Euro Celtique Sa Przydatne do leczenia bólu związki fenylowo-karboksyamidowe
PL1727801T3 (pl) * 2003-12-30 2009-08-31 Euro Celtique Sa Piperazyny użyteczne do leczenia bólu
TN2010000251A1 (fr) 2010-06-03 2011-11-11 Rekik Raouf N-acetyl-dl-leucine medicament neuro et retino protecteur
US8921373B2 (en) * 2010-06-22 2014-12-30 Shionogi & Co., Ltd. Compounds having TRPV1 antagonistic activity and uses thereof
LT2588130T (lt) 2010-06-25 2016-12-12 Shire Human Genetic Therapies, Inc. Terapinės priemonės pristatymas cns
AU2012293417A1 (en) * 2011-08-10 2013-05-02 Purdue Pharma L.P. TRPV1 antagonists including dihydroxy substituent and uses thereof
ES2994242T3 (en) 2016-04-19 2025-02-05 Intrabio Ltd Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility
DK3359146T3 (en) 2016-08-11 2019-04-08 Intrabio Ltd PHARMACEUTICAL COMPOSITIONS AND USES AGAINST LYSOSOMAL STORAGE DISEASES
WO2018029658A1 (en) 2016-08-11 2018-02-15 Intrabio Limited Therapeutic agents for neurodegenerative diseases
HUE062729T2 (hu) 2017-03-28 2023-12-28 Intrabio Ltd Betahisztin, vagy gyógyászatilag elfogadható sója, és egy monoamin-oxidáz inhibitor, egy alanyban szédülés egy vagy több tünete kezelésében vagy megelõzésében történõ alkalmazásra
IL273929B2 (en) 2017-10-18 2024-11-01 Intrabio Ltd Therapeutic agents for neurodegenerative diseases
US12458614B2 (en) 2017-10-18 2025-11-04 Intrabio Ltd Therapeutic agents for improved mobility and cognitive function and for treating neurodegenerative diseases and lysosomal storage disorders
MA51836B1 (fr) 2018-02-15 2025-01-31 Intrabio Ltd Agents thérapeutiques permettant de traiter le syndrome des jambes sans repos
EP3886986A1 (en) 2018-12-06 2021-10-06 IntraBio Ltd Deuterated analogs of acetyl-leucine
SMT202400334T1 (it) 2019-03-02 2024-09-16 Intrabio Ltd (n-)acetil-l-leucina per il trattamento di lesioni cerebrali traumatiche
RS67283B1 (sr) 2019-06-28 2025-11-28 Intrabio Ltd Kombinovana terapija sa acetil-leucinom i miglustatom za lečenje bolesti lizozomskog skladištenja
WO2021144720A1 (en) 2020-01-13 2021-07-22 Intrabio Ltd Treatment of late-onset neurodegenerative diseases in heterozygous npc1 gene mutation carriers

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4962121A (en) * 1987-04-22 1990-10-09 Anders Hamberger Method and composition for treating neurological diseases such as migraine
WO2008032222A2 (en) * 2006-09-13 2008-03-20 Pierre Fabre Medicament Treatment of vertigo with acetyl-l-leucine
CN103200940A (zh) * 2010-11-09 2013-07-10 曼金德公司 用于治疗偏头痛的包含血清素受体激动剂和二酮哌嗪的组合物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Changes in Serum Amino Acids in Migraine Patients without and with Aura and their Possible Usefulness in the Study of Migraine Pathogenesis;Izabela Domitrz等;CNS & Neurological Disorders - Drug Targets;第14卷(第3期);345-349 *

Also Published As

Publication number Publication date
MA49396B1 (fr) 2021-03-31
DK3638370T3 (da) 2021-01-25
MA49396A (fr) 2020-04-22
KR20210013518A (ko) 2021-02-04
RU2020100475A3 (https=) 2021-10-22
CN111093772A (zh) 2020-05-01
HRP20210108T1 (hr) 2021-03-19
SI3638370T1 (sl) 2021-04-30
SMT202100037T1 (it) 2021-03-15
BR112019026660A2 (pt) 2020-07-14
ZA201908087B (en) 2024-11-27
AU2018284330B2 (en) 2024-03-14
IL271211A (en) 2020-01-30
US20200253905A1 (en) 2020-08-13
PT3638370T (pt) 2021-01-26
HUE053089T2 (hu) 2021-06-28
MD3638370T2 (ro) 2021-04-30
MX2019014784A (es) 2021-11-16
JP2020526575A (ja) 2020-08-31
SG11201912146RA (en) 2020-01-30
IL271211B2 (en) 2024-01-01
AU2018284330A1 (en) 2020-01-02
KR102594130B1 (ko) 2023-10-24
EP3638370A1 (en) 2020-04-22
JP7130739B2 (ja) 2022-09-05
GB201709459D0 (en) 2017-07-26
LT3638370T (lt) 2021-03-25
EP3638370B1 (en) 2020-11-11
CY1123860T1 (el) 2022-05-27
ES2847169T3 (es) 2021-08-02
PL3638370T3 (pl) 2021-05-17
IL271211B1 (en) 2023-09-01
RS61481B1 (sr) 2021-03-31
CA3067321A1 (en) 2018-12-20
MX387909B (es) 2025-03-19
RU2020100475A (ru) 2021-07-14
WO2018229738A1 (en) 2018-12-20
US11471434B2 (en) 2022-10-18

Similar Documents

Publication Publication Date Title
JP7506046B2 (ja) 改善される運動性及び認知機能のためのアセチル－ロイシン又はその薬学的に許容される塩
CN111093772B (zh) 偏头痛的治疗
KR102693607B1 (ko) 하지 불안 증후군을 치료하기 위한 치료제
RU2772278C2 (ru) Лечение мигрени
CA3067321C (en) Use of acetyle-leucine to prevent and/or treat migraine
HK40023292B (en) Treatment of migraine with acetyl-leucine
HK40023292A (en) Treatment of migraine with acetyl-leucine
BR112019026660B1 (pt) Uso de acetil-leucina ou seu sal para preparação demedicamento para tratar ou prevenir enxaqueca ou sintomas associados
WO2021231582A1 (en) Nitro-aminoadamantane compounds for the treatment of negative symptoms and cognitive impairment associated with schizophrenia
HUE027934T2 (en) Combination for the prevention and treatment of behavioral, mental and cognitive disorders
HK40036165B (en) Acetyl-leucine for use in treating restless leg syndrome
HK40036165A (en) Acetyl-leucine for use in treating restless leg syndrome
BR112020007657B1 (pt) Uso de leucina, acetil-leucina ou um sal farmaceuticamente aceitável da mesma para tratamento da síndrome das pernas inquietas (rls)
WO2019028298A1 (en) USE OF TYROSINE KINASE ABELSON INHIBITOR IN THE TREATMENT OF MULTISYSTEMIZED ATROPHY

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
CB02 Change of applicant information
CB02 Change of applicant information

Address after: England Atsushi

Applicant after: INTRABIO Ltd.

Address before: Ushizu gun

Applicant before: INTRABIO Ltd.

SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant